Search Results - "Tollefson, G. D."

Long-term olanzapine treatment : Weight change and weight-related health factors in schizophrenia by KINON, Bruce J, BASSON, Bruce R, GILMORE, Julie A, TOLLEFSON, Gary D

“…Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in…”
Get full text

Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression by Bech, P., Cialdella, P., Haugh, M. C., Birkett, M. A., Hours, A., Boissel, J. P., Tollefson, G. D.

“…Previous meta-analyses of fluoxetine as an antidepressant have many methodological problems, including diagnosis of major depression, validity of outcome…”
Get full text

A Novel Augmentation Strategy for Treating Resistant Major Depression by Shelton, Richard C., Tollefson, Gary D., Tohen, Mauricio, Stahl, Stephen, Gannon, Kimberley S., Jacobs, Thomas G., Buras, William R., Bymaster, Frank P., Zhang, Wei, Spencer, Kimberley A., Feldman, Peter D., Meltzer, Herbert Y.

“…OBJECTIVE: Treatment-resistant depression is a significant public health concern; drug switching or augmentation often produce limited results. The authors…”
Get full text

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone by BASSON, Bruce R, KINON, Bruce J, TAYLOR, Cindy C, SZYMANSKI, Keith A, GILMORE, Julie A, TOLLEFSON, Gary D

“…Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine,…”
Get full text

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial by TOLLEFSON, G. D, BEASLEY, C. M, TRAN, P. V, STREET, J. S, KRUEGER, J. A, TAMURA, R. N, GRAFFEO, K. A, THIEME, M. E

“…OBJECTIVE: This international, multicenter double-blind trial was designed to compare the therapeutic profile of an atypical antipsychotic, olanzapine, with…”
Get full text

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine by TOLLEFSON, G. D, SANGER, T. M

“…OBJECTIVE: The authors investigated whether primary negative symptoms of schizophrenia are enduring or treatment-responsive. METHODS: Previously, a…”
Get full text

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders by TRAN, P. V, HAMILTON, S. H, KUNTZ, A. J, POTVIN, J. H, ANDERSEN, S. W, BEASLEY, C. JR, TOLLEFSON, G. D

“…Olanzapine and risperidone, both second-generation antipsychotic agents, represent two different pharmacologic strategies. Although they share some in vitro…”
Get full text

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex by Zhang, Wei, Perry, Kenneth W, Wong, David T, Potts, Brian D, Bao, Jingqi, Tollefson, Gary D, Bymaster, Frank P

“…To understand the mechanism of the clinical efficacy of olanzapine and fluoxetine combination therapy for treatment-resistant depression (TRD), we studied the…”
Get full text

Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis by Sanger, Todd M., Lieberman, Jeffery A., Tohen, Mauricio, Grundy, Starr, Beasley, Jr, Charles, Tollefson, Gary D.

“…OBJECTIVE: It has been hypothesized that the morbidity and mortality associated with schizophrenia can be prevented by providing effective treatment during the…”
Get full text

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol by TOLLEFSON, G. D, BEASLEY, C. M, TAMURA, R. N, TRAN, P. V, POTVIN, J. H

“…OBJECTIVE: Tardive dyskinesia is a serious and common complication of neuroleptic treatment. Olanzapine is a novel antipsychotic agent exhibiting regional…”
Get full text

Safety of olanzapine by BEASLEY, C. M, TOLLEFSON, G. D, TRAN, P. V

“…Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized. The primary clinical trial…”
Get full text

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations by Crawford, Ann Marie K., Beasley, Charles M., Tollefson, Gary D.

“…Prolactin elevation is both a common and a persistent event with the currently marketed antipsychotics, excluding clozapine. Elevations have been associated…”
Get full text

A Double-Blind, Controlled Comparison of the Novel Antipsychotic Olanzapine versus Haloperidol or Placebo on Anxious and Depressive Symptoms Accompanying Schizophrenia by Tollefson, Gary D., Sanger, Todd M., Beasley, Charles M., Tran, Pierre V.

“…Background: Depressive symptoms are a common feature of schizophrenia and may represent a core part of the illness. Where present, it has been associated with…”
Get full text

Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses by Tran, P V, Dellva, M A, Tollefson, G D, Wentley, A L, Beasley, Jr, C M

“…Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses. Data were from double-blind…”
Get more information

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia by TRAN, P. V, DELLVA, M. A, TOLLEFSON, G. D, BEASLEY, C. M, POTVIN, J. H, KIESLER, G. M

“…A relative lack of extrapyramidal symptoms (EPS, i.e., the syndromes of dystonia, parkinsonism, akathisia, dyskinesia) is one criterion used to determine…”
Get full text

Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features by TOLLEFSON, G. D, HOLMAN, S. L, SAYLER, M. E, POTVIN, J. H

“…The presence or absence of anxiety has traditionally determined choice of an antidepressant ("activating" or "sedating"); however, there is little scientific…”
Get full text

Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms by Poyurovsky, M, Dorfman-Etrog, P, Hermesh, H, Munitz, H, Tollefson, G D, Weizman, A

“…Some studies suggest that obsessive-compulsive symptoms may be common (7.8-46%) in schizophrenic patients and seem to be poorly responsive to drug therapy…”
Get more information

Cognitive function in schizophrenic patients by TOLLEFSON, G. D

“…Cognitive impairment is a relatively frequent aspect of schizophrenia. Deficits are most prominent in tasks involving attention, memory, and executive…”
Get full text

The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone by Tollefson, Gary D, Andersen, Scott W, Tran, Pierre V

“…Background: Depressive symptoms are common during the course of schizophrenia and may carry prognostic relevance. Methods: From a 28-week prospective,…”
Get full text

Outcome Assessment and Clinical Improvement in Panic Disorder: Evidence From a Randomized Controlled Trial of Fluoxetine and Placebo by Michelson, David, Lydiard, R. Bruce, Pollack, Mark H., Tamura, Roy N., Hoog, Sharon L., Tepner, Rosalinda, Demitrack, Mark A., Tollefson, Gary D., the Fluoxetine Panic Disorder Study Group

“…Objective:Although panic attacks account for only a portion of the morbidity of panic disorder and panic attack frequency assessments are unreliable, studies…”
Get full text